Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 4/20 | 0.42 |
| ▸ | BRD4 | O60885 | 10/20 | 0.36 |
| ▸ | FPR3 | P25089 | 2/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30797730 | 0.88 | ATR (0.44) | ATRBRD4FPR3FPR2TLR2 | |
| SCHEMBL30869111 | 0.88 | ATR (0.41) | ATRBRD4TLR2TLR1CA12 | |
| SCHEMBL30869149 | 0.87 | ATR (0.47) | ATRBRD4FPR3FPR2CA12 | |
| SCHEMBL30869075 | 0.86 | ATR (0.40) | ATRBRD4TLR2TLR1ATRIP | |
| SCHEMBL30869064 | 0.86 | ATR (0.41) | ATRBRD4FPR3FPR2TLR2 | |
| SCHEMBL30868992 | 0.85 | ATR (0.42) | ATRBRD4TLR2TLR1ATRIP | |
| SCHEMBL30869097 | 0.79 | ATR (0.47) | ATRBRD4CA12CA1CA2 | |
| SCHEMBL30797740 | 0.79 | ATR (0.43) | ATRBRD4FPR3FPR2CA12 | |
| SCHEMBL30797968 | 0.78 | ATR (0.51) | ATRBRD4FPR3FPR2CA12 | |
| SCHEMBL27376610 | 0.78 | ATR (0.51) | ATRBRD4FPR3FPR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024052702-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2024-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | ATR 984/4885BRD4 169/4885FPR3 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.